Cargando…
Multielectrode Radiofrequency Ablation for Resectable Metachronous Liver Metastasis from Colorectal Cancer
The outcome of radiofrequency ablation (RFA) for liver metastases from colorectal cancer (CRLM) has been thought to be inferior to metastasectomy. However, the recent development of multielectrode RFA (multi-RFA) systems has made the ablation zone larger and more complete. Thus, we assessed the surv...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396979/ https://www.ncbi.nlm.nih.gov/pubmed/34442007 http://dx.doi.org/10.3390/jcm10163712 |
_version_ | 1783744499842809856 |
---|---|
author | Cheng, Hou-Ying Huang, Kai-Wen Liang, Jin-Tung Lin, Been-Ren Huang, John Hung, Ji-Shiang Chen, Chi-Ling |
author_facet | Cheng, Hou-Ying Huang, Kai-Wen Liang, Jin-Tung Lin, Been-Ren Huang, John Hung, Ji-Shiang Chen, Chi-Ling |
author_sort | Cheng, Hou-Ying |
collection | PubMed |
description | The outcome of radiofrequency ablation (RFA) for liver metastases from colorectal cancer (CRLM) has been thought to be inferior to metastasectomy. However, the recent development of multielectrode RFA (multi-RFA) systems has made the ablation zone larger and more complete. Thus, we assessed the survival benefits of this modality in cases of metachronous CRLM. This retrospective study assessed patients diagnosed with resectable metachronous CRLM between 2013 and 2016; 132 patients were categorized by treatment for liver metastases: multi-RFA (n = 68), hepatectomy (n = 34), or systemic treatment only (n = 30). Therapeutic effectiveness, outcomes, and intervention-related complications were compared between groups. Median overall survival (OS), recurrence-free survival (RFS), and intrahepatic recurrence-free survival (IHRFS) were 69.8, 85.2, and 59.7 months for the hepatectomy group; 53.4, 41.3, and 32.3 months for the multi-RFA group; and 19.1, 7.1, and 7.1 months for the systemic treatment group. No significant differences were observed between the multi-RFA and hepatectomy groups after a median follow-up of 59.8 months. This study demonstrated that multi-RFA and hepatectomy provide similar survival benefits for patients with resectable CRLM. Multi-RFA may represent a reliable treatment option for the management of resectable liver metastases. |
format | Online Article Text |
id | pubmed-8396979 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83969792021-08-28 Multielectrode Radiofrequency Ablation for Resectable Metachronous Liver Metastasis from Colorectal Cancer Cheng, Hou-Ying Huang, Kai-Wen Liang, Jin-Tung Lin, Been-Ren Huang, John Hung, Ji-Shiang Chen, Chi-Ling J Clin Med Article The outcome of radiofrequency ablation (RFA) for liver metastases from colorectal cancer (CRLM) has been thought to be inferior to metastasectomy. However, the recent development of multielectrode RFA (multi-RFA) systems has made the ablation zone larger and more complete. Thus, we assessed the survival benefits of this modality in cases of metachronous CRLM. This retrospective study assessed patients diagnosed with resectable metachronous CRLM between 2013 and 2016; 132 patients were categorized by treatment for liver metastases: multi-RFA (n = 68), hepatectomy (n = 34), or systemic treatment only (n = 30). Therapeutic effectiveness, outcomes, and intervention-related complications were compared between groups. Median overall survival (OS), recurrence-free survival (RFS), and intrahepatic recurrence-free survival (IHRFS) were 69.8, 85.2, and 59.7 months for the hepatectomy group; 53.4, 41.3, and 32.3 months for the multi-RFA group; and 19.1, 7.1, and 7.1 months for the systemic treatment group. No significant differences were observed between the multi-RFA and hepatectomy groups after a median follow-up of 59.8 months. This study demonstrated that multi-RFA and hepatectomy provide similar survival benefits for patients with resectable CRLM. Multi-RFA may represent a reliable treatment option for the management of resectable liver metastases. MDPI 2021-08-20 /pmc/articles/PMC8396979/ /pubmed/34442007 http://dx.doi.org/10.3390/jcm10163712 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cheng, Hou-Ying Huang, Kai-Wen Liang, Jin-Tung Lin, Been-Ren Huang, John Hung, Ji-Shiang Chen, Chi-Ling Multielectrode Radiofrequency Ablation for Resectable Metachronous Liver Metastasis from Colorectal Cancer |
title | Multielectrode Radiofrequency Ablation for Resectable Metachronous Liver Metastasis from Colorectal Cancer |
title_full | Multielectrode Radiofrequency Ablation for Resectable Metachronous Liver Metastasis from Colorectal Cancer |
title_fullStr | Multielectrode Radiofrequency Ablation for Resectable Metachronous Liver Metastasis from Colorectal Cancer |
title_full_unstemmed | Multielectrode Radiofrequency Ablation for Resectable Metachronous Liver Metastasis from Colorectal Cancer |
title_short | Multielectrode Radiofrequency Ablation for Resectable Metachronous Liver Metastasis from Colorectal Cancer |
title_sort | multielectrode radiofrequency ablation for resectable metachronous liver metastasis from colorectal cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396979/ https://www.ncbi.nlm.nih.gov/pubmed/34442007 http://dx.doi.org/10.3390/jcm10163712 |
work_keys_str_mv | AT chenghouying multielectroderadiofrequencyablationforresectablemetachronouslivermetastasisfromcolorectalcancer AT huangkaiwen multielectroderadiofrequencyablationforresectablemetachronouslivermetastasisfromcolorectalcancer AT liangjintung multielectroderadiofrequencyablationforresectablemetachronouslivermetastasisfromcolorectalcancer AT linbeenren multielectroderadiofrequencyablationforresectablemetachronouslivermetastasisfromcolorectalcancer AT huangjohn multielectroderadiofrequencyablationforresectablemetachronouslivermetastasisfromcolorectalcancer AT hungjishiang multielectroderadiofrequencyablationforresectablemetachronouslivermetastasisfromcolorectalcancer AT chenchiling multielectroderadiofrequencyablationforresectablemetachronouslivermetastasisfromcolorectalcancer |